Search Results for "diltiazem"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for diltiazem. Results 1 to 10 of 48 total matches.

Nitroglycerin Ointment (Rectiv) for Anal Fissure

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2012  (Issue 1386)
channel blockers such as diltiazem, and injections of botulinum toxin A.3,4 All of these are effective ...
The FDA has approved the use of nitroglycerin ointment 0.4% (Rectiv – ProStrakan/Aptalis) for treatment of moderate to severe pain associated with chronic anal fissure; the same drug is marketed as Rectogesic in Europe. Nitroglycerin ointment 2% (Nitro-Bid) is available in the US for prevention of angina.
Med Lett Drugs Ther. 2012 Mar 19;54(1386):23-4 |  Show IntroductionHide Introduction

Drugs for Stable Angina Pectoris

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 1994  (Issue 937)
-release Procardia XL 30 to 90 mg once daily 35.54 Other Classes Diltiazem immediate release 30 to 120 ...
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Med Lett Drugs Ther. 1994 Dec 9;36(937):111-4 |  Show IntroductionHide Introduction

Amlodipine - A New Calcium-Channel Blocker

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 1992  (Issue 882)
* Amlodipine − Norvasc (Pfizer) 5 mg once daily $ 32.85 Diltiazem − Cardizem CD (Marion Merrell Dow) 180 mg ...
Amlodipine (am loe' di peen) besylate (Norvasc - Pfizer), a dihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration for once-daily oral treatment of hypertension, chronic stable angina, and vasospastic (Prinzmetal's) angina.
Med Lett Drugs Ther. 1992 Oct 30;34(882):99-100 |  Show IntroductionHide Introduction

Nisoldipine-A New Calcium-Channel Blocker for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Feb 16, 1996  (Issue 968)
for treatment of hypertension in the USA, except for verapamil and diltiazem, are dihydropyridines. Verapamil ...
Nisoldipine (Sular -Zeneca), a dihydropyridine calcium-channel blocker structurally similar to nifedipine, has been approved for marketing by the US Food and Drug Administration. It is available in an oral extended-release formulation for treatment of hypertension.
Med Lett Drugs Ther. 1996 Feb 16;38(968):13-4 |  Show IntroductionHide Introduction

Mibefradil--A New Calcium-Channel Blocker

   
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997  (Issue 1013)
coronary and peripheral blood vessels. Verapamil and diltiazem are more likely than dihydropyridines ...
Mibefradil dihydrochloride (Posicor - Roche), a chemically distinct nondihydropyridine calcium-channel blocker, has been approved by the US Food and Drug Administration (FDA) and is being heavily promoted as the first T-type calcium-channel blocker for treatment of hypertension and chronic stable angina.
Med Lett Drugs Ther. 1997 Nov 7;39(1013):103-5 |  Show IntroductionHide Introduction

Felodipine - Calcium-Channel Blocker For Hypertension

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 1991  (Issue 859)
. CALCIUM-CHANNEL BLOCKERS FOR HYPERTENSION Wholesale Drug Usual Initial Dosage Cost* Diltiazem ...
Felodipine (Plendil - Merck), an extended-release preparation of a dihydropyridine calcium-channel blocker was recently marketed in the USA for oral treatment of hypertension. An immediate-release formulation is available in some other countries.
Med Lett Drugs Ther. 1991 Dec 13;33(859):115-6 |  Show IntroductionHide Introduction

Safety of Calcium-Channel Blockers

   
The Medical Letter on Drugs and Therapeutics • Feb 14, 1997  (Issue 994)
-acting Diltiazem − immediate-release − Cardizem ✔✔ Also approved for unstable angina and some cardiac ...
Reports of increased mortality associated with calcium-channel blockers have caused concerns among patients taking these drugs and their physicians.
Med Lett Drugs Ther. 1997 Feb 14;39(994):13-4 |  Show IntroductionHide Introduction

Drugs for Cardiac Arrhythmias

   
Treatment Guidelines from The Medical Letter • Jun 01, 2007  (Issue 58)
using adenosine; other options are intravenous (IV) verapamil, diltiazem or a beta-blocker ...
The drugs of choice for treatment of common cardiac arrhythmias are listed in Tables 1 and 2. Some drugs are recommended for indications that have not been approved by the FDA.
Treat Guidel Med Lett. 2007 Jun;5(58):51-8 |  Show IntroductionHide Introduction

Isradipine For Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 31, 1991  (Issue 845)
-CHANNEL BLOCKERS FOR HYPERTENSION Drug Initial Dosage Cost* Diltiazem − Cardizem SR (Marion Merrell Dow ...
Isradipine (DynaCirc - Sandoz), a dihydropyridine calcium-channel blocker chemically related to nicardipine (Cardene) and nifedipine (Procardia, and others), was recently approved by the US Food and Drug Administration for oral treatment of hypertension.
Med Lett Drugs Ther. 1991 May 31;33(845):51-2 |  Show IntroductionHide Introduction

Ranolazine (Ranexa) for Chronic Angina

   
The Medical Letter on Drugs and Therapeutics • Jun 05, 2006  (Issue 1236)
of other dihydropyridines with ranolazine has not been studied, and use with diltiazem (Cardizem, and others) or verapamil ...
The FDA has approved the marketing of extended release (ER) ranolazine (Ranexa - CV Therapeutics) for treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs. It should be used in combination with a nitrate, a beta-blocker or the dihydropyridine calcium-channel blocker amlodipine (Norvasc), and appears to be more effective in men. The labeling for ranolazine specifies amlodipine as the calcium-channel blocker of choice because the use of other dihydropyridines with ranolazine has not been studied, and use with diltiazem (Cardizem, and...
Med Lett Drugs Ther. 2006 Jun 5;48(1236):46-7 |  Show IntroductionHide Introduction